Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch HealthBHC +14.26%64 Equity-to-Asset is -0.07 as of Jun. 2026. GuruFocus rates BHC with a GF Score™ of 64/100 and a GF Value™ of $7.73 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Bausch Health ranks worse than 92.26% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bausch Health's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $-1,771 Mil. Bausch Health's Total Assets for the quarter that ended in Jun. 2026 was $24,794 Mil.
Therefore, Bausch Health's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was -0.07.
The historical rank and industry rank for Bausch Health's Equity-to-Asset or its related term are showing as below:
BHC'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.08 Med: -0.01 Max: 0.16
Current: -0.07
During the past 13 years, the highest Equity to Asset Ratio of Bausch Health was 0.16. The lowest was -0.08. And the median was -0.01.
BHC's Equity-to-Asset is ranked worse than 92.26% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs BHC: -0.07
Bausch Health (NYSE:BHC) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Bausch Health Equity-to-Asset Related Terms
Bausch Health Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Bausch Health's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch Health Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Bausch Health's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Bausch Health's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health (BHC) has a Equity-to-Asset of -0.07 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Bausch Health and its competitors. According to the industry distribution chart, Bausch Health ranks #930 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 92.3%.
Is Bausch Health's Equity-to-Asset too high?
Bausch Health's current Equity-to-Asset is -0.07. Based on the distribution chart, Bausch Health ranks #930 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bausch Health has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #930 out of 1008 companies for Equity-to-Asset. This places Bausch Health in the lower half of its industry. The industry median Equity-to-Asset is 0.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Bausch Health and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current Equity-to-Asset is -0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (BHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.73, compared to a current price of $6.89 — trading 10.9% below its estimated fair value. The current Equity-to-Asset is -0.07. Bausch Health's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Bausch Health (BHC), the current Equity-to-Asset is -0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (BHC) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of $6.89 is trading 10.9% below its estimated GF Value™ of $7.73.
GuruFocus considers Bausch Health to be Modestly Undervalued.
Key valuation signals for BHC:
Equity-to-Asset: -0.07
GF Value™: $7.73 vs. price of $6.89 (10.9% below fair value)
No single metric tells the full story. See the BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
64GF Score
Get the complete analysis for BHC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHC has been successfully added to your 
